Why the study?
How should hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system be managed?
How should hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system be managed?
This review provides clinical guidance on managing hyperkalemia induced by RAAS inhibitors, particularly in high-risk patients.
Supports current approaches to RAAS inhibitor hyperkalemia; leaves open need for prospective trials to refine strategies.
Hyperkalemia can develop as a result of treatment with angiotensin-converting–enzyme inhibitors or angiotensin-receptor blockers. This side effect is most common in patients with risk factors such as diabetes mellitus, heart failure, chronic kidney disease, or advanced age. This review explains the pathophysiology and offers clinical guidance for management.
No takes yet. Share an insight, caveat, or question.
Biff F. Palmer (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: